Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material

Inclusion Criteria: * People aged 50 and over. * Diagnosed with bilateral or unilateral AMD. * Eyes with SHRM and type 2 or mixed (type 1 and 2) neovascular membrane. * Näive eyes treated with Faricimab following SmPC (summary of product characteristic). * They agree to participate in the study and sign the informed consent form. Exclusion Criteria: * Eyes with type 1, aneurysmal type 1 and type 3 MNV. * Eyes with type 2 MNV and other macular diseases (myopia, posterior uveitis, systemic diseases, such as pseudoxanthoma elasticum). * Eyes with ocular media opacity. * Patients with other retinal diseases, such as central serous chorioretinopathy, diabetic retinopathy, retinal vascular occlusion, uveitis, myopic maculopathy or any other retinal disease that could compromise the best-corrected visual acuity and interfere with retinal parameters. * Any neurological condition (including cognitive impairment, stroke, dementia, Parkinson, anxiety or schizophrenia) that, in the opinion of the investigator, would pose a risk to patient's safety or interfere with the assessment, procedures, or completion of the study. * People who are participating or will participate in any type of clinical trial. * Pregnant women. * Breastfeeding women. * Women\* of childbearing potential who are unable or unwilling to use highly effective methods of contraception (bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) from the start to the end of the study. * Woman of childbearing potential: considered as such if she is postmenarcheal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), or has not undergone surgical sterilization (removal of ovaries and/or uterus).